InspireMD to Announce First Quarter 2025 Financial Results
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its first quarter 2025 financial results release for May 9, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
InspireMD (NSPR), developer of the CGuard™ Prime carotid stent system for treating carotid artery disease and stroke prevention, has scheduled its first quarter 2025 financial results release for May 9, 2025.
The company will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss financial results and recent highlights. Investors can join via telephone (domestic: 1-800-579-2543, international: 1-785-424-1789) or through the company's website webcast.
Details
News Market Reaction – NSPR
The recorded move for NSPR in the trading session of this news was -0.38%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MIAMI, April 25, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease (CAD) and prevention of stroke, today announced that it will release its first quarter 2025 financial results on Friday, May 9, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights.
Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD’s website or by registering below. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on InspireMD’s website.
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1713642&tp_key=1c3c464032
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free, long-term outcomes. InspireMD’s common stock is quoted on the Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on our website. For more information, please visit www.inspiremd.com.
Investor Contact:
Craig Shore
Chief Financial Officer
InspireMD, Inc.
888-776-6804
craigs@inspiremd.com
Webb Campbell
Gilmartin Group LLC
Webb@gilmartinir.com
investor-relations@inspiremd.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.